Allogene Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
361
- Stock Symbol
-
ALLO
- Investments
-
5
- Share Price
-
$2.70
- (As of Friday Closing)
Allogene Therapeutics General Information
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Contact Information
Website
www.allogene.comCorporate Office
- 210 East Grand Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 210 East Grand Avenue
- South San Francisco, CA 94080
- United States
Allogene Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.70 | $2.61 | $2.01 - $5.78 | $565M | 209M | 2.15M | -$1.64 |
Allogene Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 190,524 | 164,765 | 451,559 | 1,693,492 |
| Revenue | 65 | 95 | 156 | 114,089 |
| EBITDA | (290,573) | (331,372) | (330,685) | (173,311) |
| Net Income | (281,930) | (327,265) | (340,414) | (182,051) |
| Total Assets | 646,883 | 642,837 | 821,579 | 1,050,828 |
| Total Debt | 86,989 | 95,121 | 101,124 | 73,129 |
Allogene Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Allogene Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Allogene Therapeutics Comparisons
Industry
Financing
Details
Allogene Therapeutics Competitors (74)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Vor Biopharma | Formerly VC-backed | Cambridge, MA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Erasca | Formerly VC-backed | San Diego, CA | ||||
| Perthera | Venture Capital-Backed | McLean, VA |
Allogene Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Allogene Therapeutics Patents
Allogene Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240228639-A1 | Cd70 anti-idiotype antibodies | Pending | 14-Dec-2022 | ||
| US-20240216430-A1 | Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof | Pending | 28-Nov-2022 | ||
| US-20240101710-A1 | B-cell maturation antigen (bcma) anti-idiotypic antibodies | Pending | 19-Sep-2022 | ||
| US-20240085403-A1 | Method for inhibiting adventitious viral infection | Pending | 16-Aug-2022 | ||
| US-20240042030-A1 | Engineered cells with reduced gene expression to mitigate immune cell recognition | Pending | 29-Jul-2022 | A61K39/4631 |
Allogene Therapeutics Executive Team (16)
| Name | Title | Board Seat |
|---|---|---|
| David Chang Ph.D | Co- Founder, Chief Executive Officer, President & Board Member | |
| Geoffrey Parker | Executive Vice President and Chief Financial Officer | |
| Timothy Moore | Chief Technology Officer, Technology & Executive Vice President | |
| Susan Lundeen | Chief People Officer | |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs, Brand Strategy Officer and Founding Member |
Allogene Therapeutics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arie Belldegrun MD | Vida Ventures (Boston) | Chairman & Founder | |
| David Bonderman JD | TPG | Board Member | |
| Deborah Messemer | Self | Board Member | |
| Elizabeth Barrett | Self | Board Member | |
| Franz Humer Ph.D | Self | Board Member |
Allogene Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Allogene Therapeutics Investments (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Antion Biosciences | 22-Jul-2023 | Biotechnology | |||
| Antion Biosciences | 11-Jan-2022 | Biotechnology | |||
| Notch Therapeutics | 10-Feb-2021 | Biotechnology | |||
| Allogene Overland Biopharm | 15-Dec-2020 | Pharmaceuticals | |||
| Notch Therapeutics | 01-Nov-2019 | Seed Round | Biotechnology |
Allogene Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 25, 2023
25.19 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Allogene Therapeutics FAQs
-
When was Allogene Therapeutics founded?
Allogene Therapeutics was founded in 2017.
-
Who is the founder of Allogene Therapeutics?
David Chang Ph.D is the founder of Allogene Therapeutics.
-
Who is the CEO of Allogene Therapeutics?
David Chang Ph.D is the CEO of Allogene Therapeutics.
-
Where is Allogene Therapeutics headquartered?
Allogene Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Allogene Therapeutics?
Allogene Therapeutics has 361 total employees.
-
What industry is Allogene Therapeutics in?
Allogene Therapeutics’s primary industry is Biotechnology.
-
Is Allogene Therapeutics a private or public company?
Allogene Therapeutics is a Public company.
-
What is Allogene Therapeutics’s stock symbol?
The ticker symbol for Allogene Therapeutics is ALLO.
-
What is the current stock price of Allogene Therapeutics?
As of 04-Oct-2024 the stock price of Allogene Therapeutics is $2.70.
-
What is the current market cap of Allogene Therapeutics?
The current market capitalization of Allogene Therapeutics is $565M.
-
What is Allogene Therapeutics’s current revenue?
The trailing twelve month revenue for Allogene Therapeutics is $65K.
-
Who are Allogene Therapeutics’s competitors?
Fate Therapeutics, Vor Biopharma, Blueprint Medicines, Erasca, and Perthera are some of the 74 competitors of Allogene Therapeutics.
-
What is Allogene Therapeutics’s annual earnings per share (EPS)?
Allogene Therapeutics’s EPS for 12 months was -$1.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
